Verona Pharma Plc (NASDAQ: VRNA)
Verona Pharma Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Verona Pharma Plc Company Info
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
News & Analysis
Why Verona Pharma Stock Is Skyrocketing Today
The company reported overwhelmingly positive results from a late-stage study of its COPD drug candidate.
Why Verona Pharma Stock Is Vaulting Higher Today
The small drugmaker reported good news about new clinical studies for its lead pipeline candidate.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.